DHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Danaher is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants an immediate, clear entry. The business fundamentals are improving, but the stock is technically weak, options sentiment is bearish, and analyst targets are being cut even though ratings remain positive. I would not call it a buy today; the better call is hold and wait for a cleaner trend confirmation.
The current price is 175.6, basically flat versus the prior close, with the broader market also weak. The chart setup is still bearish: SMA_200 > SMA_20 > SMA_5, which shows the stock remains in a downtrend/weak recovery phase. MACD histogram is -0.671 and still below zero, although the negative momentum is contracting. RSI_6 at 32.229 is near oversold but not yet a strong reversal signal. Price is sitting just below pivot resistance at 177.32 and above support at 173.141, so the stock is trading in a tight zone without a confirmed breakout. The short-term pattern stats suggest some rebound potential, but the overall trend is not strong enough to qualify as a confident buy.
["Q1 revenue grew 3.66% YoY to 5.951B.", "Q1 net income rose 7.86% YoY and EPS increased 9.85% YoY, showing operating improvement.", "Danaher approved a quarterly dividend of $0.40 per share, reinforcing shareholder returns.", "Analysts still mostly maintain Buy/Outperform ratings despite trimming targets.", "The company-specific pattern data suggests a modest upside bias over the next week and month."]
["Multiple analysts lowered price targets in late April, showing valuation expectations have reset lower.", "Gross margin declined 1.76% YoY to 60.34, indicating some margin pressure.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5.", "MACD is still negative, so momentum has not fully turned bullish.", "Options flow is clearly bearish, with heavy put demand and a put-heavy volume profile."]
In Q1 2026, Danaher posted improving top- and bottom-line performance. Revenue increased to 5.951B, up 3.66% YoY, while net income rose 7.86% YoY to 1.029B and EPS climbed 9.85% YoY to 1.45. The main weakness was gross margin, which fell to 60.34% from the prior year, down 1.76% YoY. Overall, the latest quarter was solid, with growth in revenue and earnings, but margin compression keeps the picture mixed. Latest quarter season: Q1 2026.
Wall Street remains constructive overall, but the tone has softened. UBS, Baird, Guggenheim, Jefferies, Barclays, and Evercore still lean Buy/Outperform/Overweight, but several firms cut targets from the mid-$200s down toward the $205-$250 range after Q1 and guidance reassessment. The bullish case is that headwinds are easing, valuation is not demanding, and upside still exists. The bearish case is that targets are being marked down, respiratory and legacy Pall-related pressures remain, and some analysts think the current setup is already pricing in the low end of guidance. Net view: pros are still positive, but less confident than before.
